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University of Warsaw, Poland
Reviewed by:
Alice Ravizza,





Silesian University in Opava, Czechia
Wadim Strielkowski,






This article was submitted to
Public Health Policy,
a section of the journal
Frontiers in Public Health
Received: 10 February 2021
Accepted: 25 March 2021
Published: 28 April 2021
Citation:
Maresova P, Rezny L, Peter L, Hajek L
and Lefley F (2021) Do Regulatory
Changes Seriously Affect the Medical
Devices Industry? Evidence From the
Czech Republic.
Front. Public Health 9:666453.
doi: 10.3389/fpubh.2021.666453
Do Regulatory Changes Seriously
Affect the Medical Devices Industry?
Evidence From the Czech Republic
Petra Maresova 1*, Lukas Rezny 1, Lukas Peter 2, Ladislav Hajek 1 and Frank Lefley 1
1Department of Economics, University of Hradec Kralove, Hradec Kralove, Czechia, 2Department of Cybernetics and
Biomedical Engineering, Technical University of Ostrava, Ostrava, Czechia
Background: Within the EU, some of the challenges and perceived risks now facing
medical device (MD) developers result from changes in the regulatory framework,
emphasizing safety. Therefore, medical technology companies must adopt stricter quality
assurance measures so that individual devices can be speedily tracked and retrieved in
emergency situations.
Objectives: We highlight the challenges and risks faced by the European medical
devices industry, particularly those faced by SMEs in the Czech Republic. We address
two important research questions: Q1. Do advantages from increased regulation
outweigh the additional expenses? Q2. As many MD developers are SMEs, will the new
regulatory regime result in some of those companies going out of business and therefore
impede future innovation?
Methods: The paper focuses on a single case study, with the situation and outcomes
discussed in the context of the financial results of a further 50 medical device
manufacturers marketing in the Czech Republic.
Results: Our findings suggest that the new legislation will result in improved safety,
facilitate product recalls, but the cost and administrative burden may be high. The
evidence also indicates that some SMEs may be forced to diversify to “non-medical”
products, with the inevitable loss of innovative MDs being made available to patients and
healthcare providers.
Keywords: risk, patient safety, regulation, innovation, SME, medical devices
INTRODUCTION
The European trade association for the medical technology industry (MedTech) state that “medical
technologies can save lives, improve health, and contribute to sustainable healthcare” (1). The
medical health literature (2) states, “Medical devices are used for the diagnosis, monitoring,
and treatment of virtually every disease or condition, and include familiar objects such as
simple bandages to high-end MRI scanners” regulated by Council Directive (3, 4). European
manufacturers now face the new Regulation (EU) 2017/745 to be introduced in 2021. This new
legislation not only presents issues concerning health and risk but also for society in general.
Attitudes toward regulations are perceived differently. Concern has been expressed in the
literature that the current regulatory regime formedical devices (MDs) is inadequate, biased toward
commercial interests, that innovation outpaces the development of regulatory controls, resulting in
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social and patient risk implications (5–7). de Mol (8) argues (p.
735) that “medical devices are considered to be a cornerstone
of medical technology and to enable progress in healthcare
for millions of patients.” The current regulatory regime
may, however, be putting patients at risk (9). With respect
to innovation theories, a strict interpretation of the Porter
hypothesis implies that challenging factors in the form of
heavy regulations can induce innovation because established
technologies get to be replaced by newer, more effective and safer
alternatives (10). This may be particularly true of the medical
device market, which is highly regulated, and new entrants must
fulfill many conditions. These conditions involve mainly safety
regulations but also environmental protection requirements, and
they affect multiple aspects of the development process: technical,
clinical, as well as biological. While the demanding conditions
may be seen as an obstacle, they may also prove stimulating for
innovation (11).
This industry’s characteristics are the exceptionally high
innovation potential (11), the above-average number of
innovations successfully applied to the market, the high
added value of products, and the high export potential (12).
The manufacturers of medical technologies have high-level
research and development capacities. They are also vocal in
expressing their expertise and knowledge toward the continuous
development of innovative and accelerated development (13). As
a result, such development activities in the Czech Republic often
result in products with unique properties, which are considered
innovative globally. The research, development, and production
of MDs have a long tradition in the Czech Republic (14). In
addition to the positive impact on the economic development
of the Czech Republic, the development and production of MDs
also have a direct positive impact on other sectors, especially the
health services sector (13).
The main change under the new MDR regulations focuses
on safety and risk reduction, which is to be achieved
by strict processes that lead to market authorization (15).
Medical technology companies must adopt more stringent
quality assurance measures so that individual devices can be
speedily tracked and retrieved in emergencies. Among the new
requirements introduced by the MDR is creating a unique
position to be filled by a candidate with proof of experience in
medical device regulations. This person is to be entrusted with
managing all matters related to regulatory requirements (16).
For SMEs in the Czech Republic, it can be challenging to find
an employee with such expertise. Moreover, “to obtain MDR
authorization for class III, implantable devices and high-risk class
IIb, MedTech companies will be required to present a notified
body with a large volume of clinical data that supports their
products’ clinical performance” (17).
However, from an SME perspective, the new European
legislation (highlighted in this paper) may result in a significant
proportional increase in costs and an increased administrative
burned, resulting in the impossibility for some companies
to continue developing new products and, therefore, restrain
innovation for the development of MDs.
This paper aims to highlight the challenges and risks faced by
the European medical devices industry due to recent legislation
changes, particularly those faced by SMEs in the Czech Republic.
We address two important research questions:
Q1. Do advantages from increased regulation outweigh the
additional expenses?
Q2. As a large proportion of MD developers are SMEs,
will the new regulatory regime result in some of those
companies going out of business and therefore restrict
future innovation?
It is essential to highlight and bring to the literature the perceived
risks (as a result of the proposed new legislation) facing SME
companies that currently develop innovative MDs.
Firstly, sector analysis provides an overview of the medical
device market and MD companies’ structure in the Czech
Republic. Secondly, the case study of an SME company describes
and analyses the situation from the point of view of regulation
and the impact on the functioning of this company. Regardless of
the company’s size, these problems or requirements will have to
be solved by every company.
THEORETICAL BACKGROUND
The importance of innovation in the medical device market and
the actual impact on society, the market and the economy is often
linked to regulations at national and global levels. It is essential
to state the context of the current legislative conditions in force
and to acquaint them with their possible impacts, which, for
example, some authors have mentioned in the past, both negative
and positive.
R&D, Innovation, and Regulation in the
Field of Medical Device Development
Success in medical device development is determined by the
variables of innovativeness, financial analysis and planning, user
input in the development process, and company employees’
engagement in the new product development (NPD) goals. It
follows that successful product development and placement on
the market depends on a complex interplay of factors relating
equally to business strategies, technological solutions, human
resources, and end-user involvement. Additionally, a survey
found that new global innovations accounted for only 4.4 per cent
of NPD projects in larger companies and 9.3 per cent of NPD
projects in SMEs (18).
Themedical device sector is a rapidly developing industry (19)
subjected to pressures from all sides. New technologies emerge
in fast succession. They are widely publicized, which results in
patients increasing demands for the latest inventions that are
still in the early stages of development and may require years of
honing and testing before they can be introduced to the market.
Therefore, the ever-increasing challenge of small high-tech firms
(HTSFs) is to keep up with the latest breakthroughs and come up
with ways to leverage their potential (20).
Hourd and Williams (21) conducted a case study on a sample
of 14 UK-based SMEs operating in the medical device sector.
The researchers compared the individual companies’ business
strategies and practices to determine the factors most important
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for these enterprises’ success. It was found that each stage of
the development process presents its peculiar challenges and
that all the stages are equally essential to the overall success.
This involves obtaining funding, securing partners, recruiting
staff, and setting up development milestones in the preparation
stage. Further on, success depends on conducting clinical trials,
obtaining approvals, launching the product and conducting post-
market surveillance.
Numerous obstacles can hinder the success of the enterprise.
These include external cost-related issues, such as lack of
funding (22), high implementation cost (22, 23) and the cost
of verification or certification (22). Furthermore, barriers may
present themselves in the form of unethical regulatory authorities
(24) and the difficulty of obtaining information (22).
The Importance of Regulation for
Innovation
The manufacturers of MDs cooperate with clinical workplaces to
research and develop new devices and then in the application
phase. This co-operation is essential for a high level of
medical and nursing care. Therefore, modern MDs represent a
fundamental and irreplaceable area for contemporary medicine,
which needs to be further developed and innovated (25). An
essential prerequisite for the use of innovativeMDs for increasing
the level of the healthcare provided is to create, in particular,
optimal legislative conditions for their market launching.
It is difficult to draw any definitive conclusions when it
comes to the relationship between regulation and innovation.
The association is a highly complex one, and the impact of
regulation on innovation is not always immediately apparent.
This impact may be manifested indirectly and gradually, such
as in subtle shifts in market structure in competition, business
strategies and investment priorities (11).
The new legislation’s key goal, highlighted in this paper,
is to provide a more transparent, efficient and “consumer-
oriented” approach and increase patient safety. The effects of
regulation on product quality have been frequently researched
in the past. While many theoretical models illustrate the
relationships between product quality, competition on the
market, and price regulation, only a few studies describe
the relationship between regulatory policies and technological
innovation. However, a positive relationship between heavy
regulation and innovation was established in the Porter
hypothesis (10), which proposed the innovation effect of
introducing innovative environment-friendly processes as a
result of heavy environmental regulations. Simultaneously,
innovative technologies are cost-efficient, compensating for any
costs incurred in achieving compliance with new regulations.
Furthermore, innovations stimulated through regulations can be
further utilized through patenting, which ultimately serves as a
competitive advantage over companies that are not subjected to
such strict regulations.
In contrast, studies that illustrate a negative impact of
regulations on innovation (26) highlight that hospitals’
regulatory obligations significantly slowed down the spread
of CT scans, which eventually became more prevalent in
individual physicians’ offices than in hospitals. Peltzman (27),
researching the effects of new FDA regulations on the drug
industry, reports that the regulations led to a significant drop
in the number of new drugs introduced in the market and
that the costs exceeded any potential savings. Finally, some
studies (28, 29) confirm that the new FDA regulations resulted
in companies cutting down investments in innovation, hence
decreasing the number of new drugs introduced.
What will be the possible consequences of the new medical
device regulations [(MDR) 2017/745]? Will it support or
hinder innovation?
Regulatory
Medical technologies are characterized by a constant flow
of innovation, resulting from a high level of research and
development within the industry and co-operation with users.
New product development can take from 1 to 2 years in terms
of their risk class. Health means are divided into classes I, IIa,
IIb, III. The placing on the market of a new or innovated product
depends on the complexity of meeting the essential requirements
and, above all, on time required for the conformity assessment by
the notified body (NB).
The following risk classifications and descriptions are taken
from (17).
Class I [I (low-risk non-sterile), Is (sterile), Im (measure),
Ir (reusable)] – Provided sterile “and/or have a measuring
function (low/medium risk) or reusable low-risk Class I devices
placed on the market in a sterile condition, have a measuring
function or are reusable surgical instruments: assessment of the
technical documentation relating only to those specific features
of the device, such as sterility, measurement, or reprocessing”
[see also (30)].
Class IIa (medium risk) “Class IIa devices: Assessment of the
technical documentation for at least one representative device for
each category of devices” [see also (31)].
Class IIb (medium/high risk) Class IIb “implantable devices
(except sutures, staples, dental fillings, dental braces, tooth
crowns, screws, wedges, plates, wires, pins, clips, and connectors)
and Class IIb active devices intended to administer and/or
remove a medicinal product: Assessment of the technical
documentation for” [see also (32)].
Class III (high risk). Class III devices: “Assessment of the
technical documentation for every device.”
Within the European Union, the medical device industry,
from development through manufacturing to distribution, is
subject to EU directives and regulations. The difference between
the two is that directives must be embedded in each member
state’s national legislative system, whereas regulations apply
directly. Legislation concerning medical devices (in the Czech
Republic, where our study is based) is spread across a number
of different directives, decrees and laws issued by the Ministry
of Health of the Czech Republic. These documents apply to
medical devices in general or to specific types of devices, such
as active implants or in vitro diagnostic devices. As an example of
legislative conditions, the European manufacturers face the new
Regulation (EU) 2017/745 (33) of the European Parliament and
the Council on Medical Devices (MDR). Currently, MDs in the
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Czech Republic are regulated by Act No. 268/2014 Coll. Like the
national laws of the other member states of the European Union,
this law incorporates Council Directive 93/42/EEC (MDD) on
MDs (34).
After placing on the market, MDs must be monitored, and
their clinical benefit and, where appropriate, the risks arising
from their use must be continuously evaluated. According to
Article 10 of the MDR, the manufacturer must set up a so-
called proactive way to establish, document, implement, and
periodically update the risk management system or conduct
a clinical trial under the requirements of Article 61 of the
MDR, including post-market clinical follow-up (PMCF) (35).
The PMCF is a requirement included in the current MDD,
allowing manufacturers to start PMCF studies before the end
of the MDD. The clinical data from these studies will be used
for MDR clinical trials, thus partially avoiding costly clinical
trials. However, manufacturers often have only a post-market
surveillance (PMS) process, which they understand as a summary
of sales and production; the collection of clinical data is only
marginally included here. For this reason, manufacturers lack
clinical data that they could rely on in their MDR clinical
trials, which can mean high financial demands, not only for the
implementation of clinical trials.
The factors mentioned above highlight the European MDs
industry’s challenges due to recent legislation changes, especially
by SMEs. MDR was due to come into force in May 2020, but
due to the COVID-19 situation, it has been postponed until May
2021. This gives manufacturers more time and the opportunity
to start taking steps to facilitate the transition to MDR. Even
though the certificate will be issued and supervised according to
the MDD until the end of the transitional period, manufacturers
will already be obliged to meet the requirements of the MDR.
General View of the Medical Device
Industry, Specifically in Europe
The development of a new medical device typically starts in
a small, innovation-driven company. Small companies tend to
stand at the beginning of technological progress in medical
devices for several reasons (36). Small-sized companies move
forward faster because they are easier to manage than large
corporates. The inventor and innovator is often the leader and
decision-maker, unlike in larger companies, where research,
leadership, and management form different levels. With the
innovator and executive in one person, it is significantly easier
to make informed decisions and assess possible risks.
This fact is also supported by the number of companies and
the structure of the market in Europe. There are 25,000 MedTech
enterprises in Europe, 95 per cent of them being SMEs (37, 38).
These enterprises are at the greatest risk of exiting the market
because administrative costs are often too high for them.
The Czech market is still relatively small compared to other
European markets. Demand for medical devices in the Czech
Republic in 2016-2020 is relatively constant. In 2016, market
growth was 1.3%. In 2019 it was estimated at 2%. Demand
for medical devices in the Czech Republic by type of device is
highest in areas: Catheters, cannulae and needles, orthopedic
and fracture appliances, Medical furniture, Electro-diagnostic
equipment, and medical instruments and appliances (39).
The Czech market’s opportunities lie in the aging population
connected with chronic diseases; there is also demand for
innovative products that improve efficiency and health outcomes,
such as mini-invasive surgery systems, digital image processing,
or home-care equipment (40).
RESEARCH METHODOLOGY
This paper is partly based on a single case study, considering that
a “Case study is the study of the particularity and complexity of a
single case, coming to understand its activity within important
circumstances” (41). The popularity of case study research is
increasing, especially in corporate research, as case studies
can provide insights that might not be achieved with other
approaches. However, “The important issue is to have a clear
objective, involve the right people and have access to the right
information” (42). Case studies can focus on a single case or
several cases. There are no formal requirements in a multi-
case study as to a minimum number of cases required, and
neither is there a requirement of a random selection of cases
(43). Therefore, a case study may not be representative since
the researcher simply examines such material as is available.
Although generalizations from a single case studymay be limited,
this does not distract from their importance. “Case studies can
be used to explain, describe or explore events or phenomena in
the everyday contexts in which they occur” (44). Analyzing a
particular case in detail may prove to be helpful in discovering
and describing cause-and-effect relationships and eventually
estimating possible tendencies that may apply to similar cases.
This research follows the main steps in preparing and conducting
a case study, including successively identifying a specific case,
collecting data, interpreting data, and drawing conclusions (45).
On top of that, we have performed the industry analysis in the
Czech Republic to assess how representative is the case of the
selected company in question, medical device producers, which
further enhance the usability of the performed case study.
Design
Our research is based on a single case study supported by data
from a further 50 companies. The case study SME company is
a representative of Czech manufacturers, listed in the Register
of Medical Devices, which since 2015 is a unified system for
comprehensive data management in medical devices in the
Czech Republic (46). We chose an SME company focusing
on the production of several types of MD class IIb, including
pacemakers. The fact that many studies confirm the importance
of SME companies played a role in selecting the company for
our detailed case study. Initially, we looked at the register of
the Association of Manufacturers of Medical Technology (47),
the total number of 140 companies available. We excluded in
vitro Diagnostic (IVD) manufacturers (these companies are not
affected by the examined change in legislation) and distributors.
Sixty-eight companies remained for further analysis. In the next
step, economic data were found in the database of Albertina
companies’ Economic data (48) (profit, revenues and number of
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employees) were not available for all companies. Our final set
contains 53 companies in total (Table 1).
Generally, our study was performed in the following steps:
• Sector analysis based on data of medical device companies in
the Czech Republic to;
◦ A list of MD companies was used from the register of the
Association of Manufacturers of Medical Technology.
◦ For each company information of the production of medical
devices according to the risk classes available in the database
the National Register of Medical Devices (available at:
https://eregpublicsecure.ksrzis.cz/Registr/RZPRO/) Class I-
III were included;
◦ For the included companies, economic data were added
using the Albertina database (48), and economic analysis
was done;
• Case study elaboration to show possible scenarios of the
impact of new legislation.
Data
We obtained a sizable dataset from accounting statements
and internal company information obtained directly from the
company’s representative. Our dataset covers the period of 2002–
2018, containing a total of 36 variables. Information about
company revenues corresponding to the various product classes
or services is present, alongside cost categories: salaries, material
costs, and specific costs directly related to MD developments
and their continual market approval (certification costs). Total
revenues, costs, and gross profit are also included.
The dataset is, however, not without its limitations. Since it
covers a relatively long time period, many accounting standards
changed over the analyzed period; namely, the method for
reporting employee numbers (given by full-time vs. part-time
contrasts in reporting) changed three times. This made it difficult
to obtain comparable data for the entire period.
The company representative was repeatedly interviewed,
and the selected financial variables (Table 2) were refined and
interpreted. Additionally, an interview was conducted in May
2019 to determine the company’s strategy in the reporting period.
We used IBM SPSS version 24 was to forecast the main
variables for the future company development scenario. SPSS
Time Series Modeler was used to select the most appropriate
method (exponential smoothing, univariate autoregressive
integrated moving average and multivariate) based on the best fit
to the historical data (49).
RESULTS
Innovation in the field of MDs is undertaken by SME companies.
Therefore, sector analysis which shows themedical devicemarket
in the Czech Republic, is done. Then possible scenarios of the
impact of new regulations are shown in a single case study.
Analysis – Part 1 - Medical Device Industry
in the Czech Republic
The major problem of MDR implementation is in the field
of innovation. Specifically, most innovative research in MDs is
not undertaken by big companies but by SMEs (37, 38). “Such
companies usually focus on the production of a small number
of products, meaning their margin does not allow them to pay
for all the necessary costs connected with MDR compliance”
(11). The estimated costs for SMEs to launch a new class III
MD will be between EUR 1–4 million or EUR 7–28 million if
the device must fulfill the centralized pre-market authorization
procedure requirements. A specific expert estimate associated
with the legislative conditions is given in Table 3.
The above data are an overall estimate for the MD market.
However, there are no data available on the impact of
new legislation on business results (50). Therefore, we have
prepared our specification based on several sources. We have
selected companies listed as members of the two MD producer
associations in the Czech Republic for our analysis. Our final list
consists of 50 companies whose data were relevant and available.
See section Design for detailed information. Data are displayed
in Table 4.
Increases in certification costs for conformity assessment were
quantified by a domain expert to be approximately 2.5 points
multiple of the current costs, except the MD of safety class I,
where there are no increases expected.
We used a combination of data regarding revenues, profit, and
the number of MDs in each company’s safety classes. Estimates
of the increase in certification costs were obtained by multiplying
the number of MDs in each respective safety class by the expected
rise in certification costs for that class. For companies having
multiple MD in the same safety class, coefficients were used
to lower estimated certification costs reflecting the fact that
producers often certify MD in larger batches (coefficients used
were 0.17 for safety class I; 0.26 for class IIa; 0.27 for class IIb
and 0.3 for class III). Estimated certification cost increases were
further comparedwith total revenues to obtain a percentage share
in revenues to create a reasonable estimate of the significance of
this increase for the company. Column 5 inTable 4 displays these
results for the groups of companies in our set.
Results show clearly that the estimated burden of certification
cost increases falls disproportionately on small and micro-
companies. This is because they have a relatively high share
of MDs in higher safety classes, IIb in particular, for which
certification costs are quite considerable, but total revenues
are relatively small. On top of that, Table 4 shows that profit
margins are increasing in line with the company size. The
smallest companies, on average, are even recording losses. The
red curve in Figure 1 depicts the decreasing estimated increase in
certification costs as the percentage of revenues. It is higher than
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TABLE 2 | Monitored variables.
Revenue from the resale of consumable
material
Purchase of material Cashflow
Sales of safety technical control (STC) Purchase of material for resale Foreign sources (“debt”)
Number of performed STC Purchase of material for product Goods (stock of products for sale and material for resale)
Revenue for product Average adjusted employee count Stock of material
Number of sold pieces (product) Employee wages total Total value of stored stocks (products and material)
Sales of own products and services Purchase of services, total Net Capital
Revenue for total sales Purchase of services, product certification Subsidy granted by the Ministry of Industry and Trade for the
development of a cardio stimulator
Total revenues Purchase of services, system certification Subsidy granted by the Ministry of Industry and trade for marketing
Profit before taxes Total costs Costs of marketing activities and international exhibitions (fairs)
TABLE 3 | Approximate costs related to the development of MDs (EUR).
Inactive Active Active/implants Comments
I I IIa IIb III
Time of development [year] 1 1 2 2 2
Employees HW 0 17,771 35,542 35,542 35,542 With a salary of 1,500EUR per month
SW 0 17,771 35,542 35,542 35,542 With a salary of 1,500EUR per month
other 35542 17,771 71,085 71,085 71,085 With a salary of 1,500EUR per month
Sterilization validation 0 0 1,851 1,851 1,851
Measurement validation 0 1,851 1,851 1,851 1,851
Tests el. Security 0 3,702 5,553 5,553 5,553 Not for implantable ones (joints, for stimulators)
EMC 0 1,851 3,702 3,702 3,702 EMC is not implantable (joints, it is a stimulator), but
again they have a higher price for biological evaluation
Biological evaluation 1,851 1,851 5,553 5,553 5,553 Based on type of MD
Clinical evaluation 740 740 1,851 3,702 3,702 If the clinical trial is based on a clinical trial, even millions
Type test 740 740 3702 5,553 5,553
CE Conformity Declaration 0 0 7,405 9,256 11,107 Abroad: notified body: it is IIa - 20 thousand e; IIb - 25
thousand e, III - 30 thousand e, plus supervision every
year about 5 thousand e. According to the MDR, it is
expected that it should be up to 25% more.
QMS 5,553 5,553 5,553 5,553 5,553
PMCF After placing a product on the market, the cost depends on the type of product, its use and the complexity of the study itself
(large price range); estimate for IIb is part of the Appendix.
Total 44,428 69,604 17,9193 184,746 186,598
the profit margins for the lower three groups of companies (1–19
employees, 16 companies total) with a relatively small estimated
impact on the larger companies (20–199 employees, 27 in total)
and negligible impact on the even larger companies (200–999
employees, 7) where it declines significantly to below one per cent
of revenues. Only the group of companies with the number of
employees in the range of 100–199 show a slight divergence from
the trend. This can be explained by the fact that companies in
this group have the highest average amount of registered MD’s
(34) concentrated in the safety classes IIb and III.
Analysis – Part 2 - Case Study
Our case study is based on an SME (Mediatrade – pulse
generators) operating and regulated in the Czech Republic. In the
context of the change in legislative conditions in the European
Union, the company’s crucial concern is related to its economic
development under the new legislative conditions.
Company Characteristics and Strategy
The company’s primary focus, which was established in 1994,
is external pacemakers’ EPG 10 production and medical
devices of risk class IIb. However, it is relatively new to the
MD industry, having entered the field in 2012. Secondary
activities include the sale of materials for usage in the
areas of gastroenterology, specially boot sets for endoscopic
stents (guiding, integral and pusher), disposable injector
varices; double and triple lumen catheter for ERCP, endoscope
catheters, guidewires, Nazo-biliar catheters. In area of cardiology
it produce device, cardiostimulation catheter, loader sets,
accessories, neurostimulation.
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1,500–1,999 1 9 9 10.50% 0.03
1,000–1,499 1 34 34 11.31% 0
250–499 3 14 5 3.5 0.8 1.3 14.04% 0.1
200–249 2 9 1,5 0.5 7 0 15.52% 0.25
100–199 8 34 12 0.8 8.1 5.8 5.42% 1.16
50–99 6 20.2 8,8 5.7 2.7 3 9.96% 0.86
25–49 9 21 17 0.9 1.9 0.8 6.04% 0.78
20–24 4 9.25 3.3 0.5 3.8 1.5 4.69% 2.02
10–19 5 14.5 3.2 1.2 5.6 0 2.12% 5.63
6–9 7 10 6 2.1 1.4 0.9 −16% 5.3
1–5 4 9.25 0 1.3 5 3.3 −169% 10.13
*Average sum(count) of MD’s in a given safety class and group of companies.
FIGURE 1 | Certification costs.
Innovation plays a large part in its product development
strategy. Since the company’s inception, it launched the first-
generation analog products, which it innovated into digital form
in 2013, launching its second-generation pacemaker. Based on
market demand, the third-generation product with biphasic
stimulation impulse was launched in 2017.
Gradually, with increased production, the domestic market
was largely saturated (in particular, regional hospitals were fully
secured by Mediatrade). The company also provides service for
each device in the form of an annual safety check (the historical
revenue trend is shown in Supplementary File 1B. Expansion to
foreign markets has partially been achieved.
In their business activities, various development problems
relating to certification and legislative have been addressed.
The company also faced complications in product testing or
testing in laboratories for compliance. Another challenge was
the compilation of documentation for the new product to be
satisfactory in the Czech Republic’s legislation. The solution to
these problems was partially achieved, in the early years, through
certification using external assistance. In later years, professional
activities were also dealt with by recruiting external experts.
The product’s price was determined based on the market
competition with the maximum target price of CZK 40,000. This
was because hospitals, if interested in the product, did not have
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TABLE 5 | Economic indicators in 2017.
Debt 77.41 percent The share of receivables in current assets 144.00 percent Return on EBIT 1.31 percent
Inventory turnover time 55.00 days Current liquidity 0.37 Increase/decrease in sales in−13.74 percent
Receivables turnover time 859.00 days Return on equity 0.53 percent Average monthly salary 1,519 EUR/month
Converted at the historical rates for the given years; data are from https://www.kurzy.cz/kurzy-men/historie/EUR-euro/2008/.
to issue a tender for the product up to and including CZK 40,000.
This resulted in reduced administrative costs for hospitals.
Economic Indicators of the Company
Mediatrade’s financial results show long-term growth between
2002 and 2018, with partial declines in 2007, 2012, and 2017.
The revenues follow the development GDP from 2011 to
2017. Despite the economic crisis between 2007 and 2009, the
company registered rising revenues (Supplementary File 1C.
This corresponds to the healthcare and pharmaceutical
industries’ performance in the Czech Republic, which did not
show a decline in the added value over this same period.
The company has a high debt ratio and a long turnover
of inventory and receivables. Its current liquidity points to the
ability to repay its short-term liabilities (Table 5). Mediatrade has
a value that is more typical for immediate liquidity, that is, very
low. The profitability of less than half a percentage point and
other indicators adds to an unfavorable economic prospect under
the current economic and legislative conditions.
Expected Development
To assess the company’s possible future development, we have
defined four scenarios based on the forecasts of three key
variables – revenues for consumption material, amount of
performed pacemaker safety – technical controls (STC), and the
number of products sold. The analysis of consumption material
revenues with exponential smoothing and the prediction of
growing revenues resulted in EUR 114,708, EUR 120,760, and
EUR 126,813 for 2020, 2021, 2022, respectively. This is based on
the historical data for the same variable with observed growth
of roughly 150% in the last 10 years and represents a simple
trend extrapolation, i.e., analyst estimate. The level of uncertainty
concerning this estimate is quite considerable, at around 50%
of the forecasted mean value (Upper confidence limit of 148
118 EUR, lower confidence limit of 81 298 EUR on the 95%
confidence level for the year 2020). Based on historical data
for the amount of performed STC’s (usually performed once a
year for each device to verify that it functions correctly, i.e.,
output signal precision is within defined bounds), the SPSS Time-
series modeler selected ARIMA (0,0,0) was used for this data
series, which equals an interpolation data series in terms of its
mean value. In terms of model fit, R-squared was negligible. The
prediction does not seem helpful, and consequently, it was not
used for further analysis. Fortunately, we know that the amount
of performed safety – technical controls each year – is determined
by the total number of pacemakers in the Czech Republic
hospitals. Mediatrade already reached a cap of 270 active
pacemakers in Czech hospitals, so the constant forecast of the 342
performed STC is relevant for the Czech market, given current
safety regulations regarding this MD’s maintenance. For the last
variable, the number of sold pacemakers, the simple exponential
smoothing method was used, with a constant predicted value
of 48 pieces sold each year. This again corresponds relatively
well to our expectations becauseMediatrade has already captured
the Czech market, and any further growth in product sales may
have to come from foreign markets. It is necessary to point
out that the trajectories mentioned above of the three primary
sources of revenue for the company do not represent exact
statistical projections but more so analyst estimates, based on
the knowledge of the company inner workings and processes
accompanied by an understanding of the Czech market for this
particular kind of MD. Costs were calculated using historical
data for the corresponding categories; for details, please see the
collected data on Mediatrade in Supplementary File 2.
The first scenario is the business-as-usual scenario (BAU),
in which there are no significant changes regarding the costs
related to MD certification and the sales volume is based on
the forecasts explained in the previous paragraph. In the second
scenario, the company is faced with increased certification
expenditures (CERT) to maintain its MD sales on the Czech
medical market. Two following scenarios are based on possible
mitigation strategies the company could adopt to offset impacts
of CERT scenario – CERT+EXP based on a pro-export company
orientation, where it expands on foreign markets with the help
of increased marketing expenditures, and CERT+PRIC, where
it tries to mitigate the increased certification costs through an
increase of 15 per cent in the price of its services and products.
We assume inelastic demand for the MD, so the predicted
volumes of the units sold and service check-ups decrease by
7.5 per cent overall. The results of this exercise are shown
in Figure 2.
Under the BAU scenario, the company generates a small
profit over the 3-year forecast period. However, once the
increased certification expenditures are included in the CERT
scenario, the firm incurs a significant loss, which further
impairs its financial standing (EUR 195,160 in debt in
2016). The first mitigation strategy, CERT+EXP, somewhat
improves the situation. However, the company still incurs a
loss, as the increased volume of sales abroad requires higher
marketing expenses and slightly higher employee costs. The last
strategy, CERT+PRIC, is the closest to zero, with a small loss
of EUR 2,444.
Regarding identified uncertainty around forecasted sales of
consumption material, the risk is disproportionally skewed to
the downside of the forecasted mean value in the post COVID-
19 world. A lower confidence limit for the first forecasted year
represents a decline of EUR 27,649, enough to wipe out the whole
profit in the BAU scenario and significantly deepen the losses in
Frontiers in Public Health | www.frontiersin.org 8 April 2021 | Volume 9 | Article 666453
Maresova et al. Regulatory Changes in the Medical Device Market
FIGURE 2 | Cumulative profit/loss.
FIGURE 3 | Development of revenues and costs under the simulated scenarios.
the rest of the scenarios. Also important is the distribution of
the results over time due to cashflow consideration; the temporal
distribution is depicted in Figure 3.
The first 3 years are based on the historical data obtained from
financial statements, and the simulation results are presented for
2020–2022. In all scenarios, losses are concentrated in the first
simulation year, but in the two final scenarios, the firm generates
a slight profit, except for the BAU scenario.
DISCUSSION
Previous studies [see, for example, (7)] highlight the need for
regulatory change. The current regime appears to be biased
toward MD producers and not the end users’ safety and risk
assessment. Kent and Faulkner (5) argue (p. 189), “that there
are weaknesses in the regulation of medical devices and that
commercial interests have dominated regulatory policy,” and
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(p. 191), “The processes of innovation outpace the development
of regulatory controls.” There has also been concern expressed
about the increasing number of MD recalls (2). Leiter and White
(6) argue that “medical devices are increasingly being implanted
in human bodies, constituting manufactured risks.”
One of the biggest problems for companies appears to be
in acquiring clinical data, which will enable them to succeed
in the conformity assessment or certification process, according
to MDR 2017/745. Until now, MDD 93/42/EC requirements
were perceived differently; the MEDDEV recommendations
specified them. However, they were still recommendations.
Within the MDR 2017/745, it is no longer a recommendation
but a regulation. Thus, there is an obligation for manufacturers
to demonstrate clinical data. However, it is not entirely clear
whether clinical data from clinical trials or data from PMCF
studies will suffice. Manufacturers believe that a well-designed
PMCF process will provide them with sufficient quality clinical
data to demonstrate their product’s clinical safety. However,
the rightly set PMCF process is an intervention in the
economic situation of the company. It is the right time for
manufacturers to decide what changes they will make to their
processes and business model to avoid the financial impact on
their business.
As the new regulations come into effect, 2021 will be a
challenging year for many companies in the MD market.
The legislative changes aim to make MDs safer for patients
throughout their lifetime. For companies, this means additional
control costs, even after an MD has been launched and also new
clinical trials for MDs with a lower risk class than in the past.
From our research, it is clear that SMEs will be most
affected by the change in legislation. Larger companies are
better positioned to adapt to legislation changes because they
already have a regulatory department to monitor and update
the legislative requirements for their currently manufactured
medical devices. Article 15 of MDR 2017/745 specifies that a
manufacturer is required to have at least one person within his
organization demonstrating his expertise in regulatory affairs,
but at the same time admits that small firms may have such
a person employed externally. From this point of view, the
response to legislative changes in small companies will not be
as dynamic as in companies that have established an internal
regulatory department. These companies will be forced to make
many changes that will impact their economic indicators.
Our market analysis shows that the larger the company the
lower the percentage change in increased costs caused by the
MDR new requirements. In our dataset, it was also apparent
that, in general, micro-cap companies are specialized in the
production of a few MDs in higher safety classes. Therefore, they
will be disproportionately affected by new regulations, estimates
of increases in certification costs as % of revenues are height.
Larger companies focus on the large-scale production of class I
MD’s where it is harder to compete by small companies due to the
economies of scale. That leads to specialization on MD’s in more
demanding safety classes, which will, unfortunately, be harder
hit by increases to certification costs. The above-mentioned leads
to a potentially threatening situation for SME’s. The performed
sectoral analysis further showed that the results obtained in the
case study of Mediatrade are relevant in the Czech Republic case,
as micro-cap companies (see Figure 1) share many of the same
characteristics in general.
Overall, there is another problem in the medical device
market, corruption. According to Transparency International’s
Index, the Czech Republic is one of the countries with a higher
level of corruption. In the CR are identified illegal and non-
standard methods of tendering and vendor lock-in Competitive
Procedures Without Negotiation (CPWN). It allows to get the
contract to a single bidder without a competition (Act 134/2016
Coll., § 63). In its reports, the Supreme Court repeatedly draws
attention to CPWN’s practices in securing public procurement,
including at the level of ministers and institutions responsible
for the purchase of medical devices and equipment. In the
years 2011-2016, the share of these contracts ranged from 31
to 62% of their total volume. A common problem with non-
standard methods in the health sector is the vendor lock-in,
it means propriety lock-in or customer lock-in that makes a
customer dependent on a vendor for products and services. Then
the contracting authority often tends to compete for long-term
contracts in closed procedures, for higher prices on the account
of public funds. One of the specific examples in the field of
healthcare is the creation of a cartel for the supply of medical
equipment and modern technologies to the Czech hospitals (50).
There is also pressure from the pharmaceutical and medical
device industry toward the use of more profitable products.
There is no definition of the standard health care covered by
the insurance as guaranteed by the law. It happened in the past
that the regulation was ad-hoc and usually even retrospective
(51). This fat is confirmed by the European Research Centre
for Anti-Corruption and State-Building (ERCAS), the Czech
Republic has been one of the most successful Centre and Eastern
European countries in the fight against corruption in all areas,
including the healthcare sector. Nowadays, its administrative
simplicity and transparency are comparable to European
standards as a result of the harmonization of laws within the
European Union (52).
CONCLUSIONS
Concerning the development of MDs, the EU regulations’
changes present many challenges to the MD industry. The new
stricter (heavy) regulations aim to improve patient safety through
more rigorous quality assurance measures, but there is concern
that this may adversely affect SMEs.
The Porter hypothesis implies that heavy regulation induces
innovation while, on the other hand, there is a contrary view that
heavy regulation is a barrier to innovation. Within the context
of the new MD development regulations discussed in this paper,
it would appear that, with respect to SMEs, heavy regulation
may be a barrier to the innovation of new MDs. In contrast,
with regard to larger organizations, such regulation may prove
to stimulate innovation. However, while some SMEs may move
away from MD development to non-MD products, they may
transfer their innovative skills to these products to the medical
profession’s detriment.
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Regarding research question Q1, our research shows that the
new regulations should ensure improved MD safety. However,
the economic load may be excessive both to the producer and
healthcare provider. A problem is not only the price of the
conformity assessment process, which in the Czech Republic
varies with regard to the type and risk class of MD in the range
of CZK 150–600 thousand within the assessment according to
MDD 93/42/EEC but another difficulty for the manufacturer is
the obligation to submit clinical data for conformity assessment.
Obtaining clinical data that can be used for MDs’ clinical trials
and subsequently setting up the PMCF system in clinical trials
may also be beyond small companies’ power. The evidence also
indicates that some SMEs may be forced to diversify to “non-
medical” products, with the inevitable loss of some innovative
MDs being made available to patients and healthcare providers.
Q2 has partly been answered under Q1, but as the number
of MD developers reduces so will the number of innovative
MDs, thus restricting future MD innovation. Following the
introduction of the new regulations, further research should be
undertaken to verify our findings and perceived implications for
the development of MDs by SMEs. On a more positive note, due
to the effect of COVID-19, the implementation of the regulations
has been delayed until 2021, giving companies the chance to
manage the transition more positively and even seek out benefits
through the opportunity of a competitive advantage.
Limitations regarding our study may arise from two
perspectives; (i) the paper deals only with the production of MDs
subject to MDD 93/42/EC, resp. MDR 2017/745 and does not,
therefore, include MDs in class IVD, and (ii) it is based mainly
on a single case study – Mediatrade. Due to the specifics of the
selected company, namely its unique business model, previously
received state subsidies and historical changes in the Czech
accounting practices disallow exact replication of this case study.
We have addressed this issue by supporting our research with a
comprehensive analysis of the whole industry, which confirms
the results obtained from Mediatrade. Nevertheless, we believe
that the paper provides a valuable contribution to the literature
concerning the innovative development of medical devices.
We believe the paper is timely in that it addresses an
important current issue regarding the MD industry’s future.
In further support of the timely relevance of our paper is the
concern regarding the current crisis over coronavirus (COVID-
19), where innovation in medical devices, especially in the field of
personal protective equipment (PPE) and respiratory/intensive
care ventilator equipment, should be encouraged and not
suppressed through restrictive legislation, although safety must
be paramount. This article can also be a basis for further research
and addressing issues such as what has happened after that date
to confirm the concerns expressed before introducing the new
regulations or refute them. How have the SMEs reacted to the
new regulations? Has there been a decline in MD innovations?
Have some SMEs gone out of business or moved away from
MD development? What impact could Covid 19 have on the
MD industry?
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